Prudential Financial’s Cartesian Therapeutics RNAC Stock Holding History

Prudential Financial’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,417	Closed	-$27.6K	–	2768
2024 Q1	$27.6K	Buy	1,417 +287	+25%	+$6.08K	﹤0.01%	2636
2023 Q4	$23.4K	Hold	1,130	–	–	﹤0.01%	2608
2023 Q3	$35.9K	Sell	1,130 -220	-16%	-$7.35K	﹤0.01%	2533
2023 Q2	$45.4K	Buy	1,350 +203	+18%	+$7.27K	﹤0.01%	2543
2023 Q1	$47.8K	Hold	1,147	–	–	﹤0.01%	2501
2022 Q4	$38.9K	Buy	1,147 +247	+27%	+$10.5K	﹤0.01%	2518
2022 Q3	$44K	Hold	900	–	–	﹤0.01%	2565
2022 Q2	$35K	Buy	900 +556	+162%	+$16.5K	﹤0.01%	2599
2022 Q1	$13K	Buy	+344	New	+$21.5K	﹤0.01%	2590
2021 Q4	–	Sell	-1,391	Closed	-$174K	–	2685
2021 Q3	$174K	Buy	+1,391	New	+$168K	﹤0.01%	2497

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Prudential Financial's RNAC Position: Q2 2024 in Review

Prudential Financial sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 1,417 shares — an estimated $27.6K sold.

Prudential Financial first reported a position in RNAC in Q3 2021 and held it in 10 quarters. The position peaked at $174K in Q3 2021. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

Prudential Financial reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
Prudential Financial sold 1,417 Cartesian Therapeutics shares in Q2 2024, an estimated $27.6K.
Prudential Financial first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 10 quarters.
Prudential Financial's Cartesian Therapeutics position peaked at $174K in Q3 2021.
61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Prudential Financial's 13F filing for Q2 2024, filed 13 Aug 2024.